A Whole Genome In Vivo CRISPR Screen in Primary ALL Predicts the Relapse
K Dormon, E Latif, D Pal, M Bashton, M Selby, H Blair, V Rand, A Hall, J Vormoor, O Heidenreich · Klinische Pädiatrie · 2016 · Heft 05
Bibliografische Angaben
Zusammenfassung
Introduction: Investigating gain of drug resistance in ALL is complicated by questions about a suitable model, cell lines are by and large not drug naïve and patient material does not grow well in vitro. To this end we have sought to show that CRISR Cas9 genome editing technology can be used in patient derived ALL material in vivo to study emergence of drug resistance. Methods: We used primografted material from patient L707, who initially presented with a Dexamethasone (DEX) sensitive t(17;19) ALL, but relapsed 5 months later. Presentation cells were transduced with the full genome GeCKOv2 CRISPR library before…
